Metformin Sensitises Osteosarcoma to Chemotherapy Via the IGF-1R/miR-610/FEN1 Pathway.

Suwei Dong,Yanbin Xiao,Ziqiang Zhu,Xiang Ma,Zhuohui Peng,Jianping Kang,Jianqiang Wang,Yunqing Wang,Zhen Li
DOI: https://doi.org/10.4081/ejh.2023.3612
2023-01-01
European Journal of Histochemistry
Abstract:Metformin can enhance cancer cell chemosensitivity to anticancer drugs. IGF-1R is involved in cancer chemoresistance. The current study aimed to elucidate the role of metformin in osteosarcoma (OS) cell chemosensitivity modulation and identify its underlying mechanism in IGF-1R/miR-610/FEN1 signalling. IGF-1R, miR-610, and FEN1 were aberrantly expressed in OS and participated in apoptosis modulation; this effect was abated by metformin treatment. Luciferase reporter assays confirmed that FEN1 is a direct target of miR-610. Moreover, metformin treatment decreased IGF-1R and FEN1 but elevated miR-610 expression. Metformin sensitised OS cells to cytotoxic agents, while FEN1 overexpression partly compromised metformin’s sensitising effects. Furthermore, metformin was observed to enhance adriamycin’s effects in a murine xenograft model. Metformin enhanced OS cell sensitivity to cytotoxic agents via the IGF-1R/miR-610/FEN1 signalling axis, highlighting its potential as an adjuvant during chemotherapy.
What problem does this paper attempt to address?